RenovoRx completes enrollment in Phase III TIGeR-PaC pancreatic cancer trial
RNXT•Phase III trial reaches final follow-up
RenovoRx completed patient enrollment in its Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, moving the program into final follow-up.
Results have not been presented; top-line data is expected in the second half of 2027 once the study reaches its required number of events.
Trial tests RenovoCath drug delivery approach
The trial tests whether targeted intra-arterial delivery of gemcitabine using the RenovoCath device can improve overall survival versus standard intravenous chemotherapy.
RenovoCath is already FDA-cleared, positioning the readout as a key catalyst for broader adoption of the company’s drug-device treatment approach.
